Three-Pronged attack on advanced lung cancer begins human testing
NCT ID NCT07355205
Summary
This study is testing whether adding a new immune-boosting drug (nogapendekin alfa inbakicept) to two existing cancer immunotherapy drugs (nivolumab and ipilimumab) works better for advanced non-small cell lung cancer. Researchers will enroll 26 patients with stage IV or recurrent lung cancer who haven't had prior treatment for their advanced disease. The main goal is to see if this three-drug combination keeps the cancer from growing longer than the standard two-drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.